-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Barinthus Biotherapeutics plc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2021 to 2023.
- Barinthus Biotherapeutics plc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$37K, a 92.8% increase year-over-year.
- Barinthus Biotherapeutics plc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$3.08M, a 29.1% increase from 2022.
- Barinthus Biotherapeutics plc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$4.34M, a 3545% decline from 2021.
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)